OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press34510.17650/1818-8346-2019-14-2-24-28HEMATOLOGIC MALIGNANCIES: TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯRecurrent deep vein thrombosis in children with malignant blood diseases: literature reviewРецидивирующее течение тромбозов глубоких вен у детей со злокачественными заболеваниями крови: обзор литературыhttps://orcid.org/0000-0003-1443-4902MorozovaD. S.МорозоваД. С.
Russian Federation

1, Samory Mashela St., Moscow 117997, Russia

Россия, 117997 Москва, ул. Саморы Машела, 1

darsmorozova@gmail.comhttps://orcid.org/0000-0003-2801-7421EvstratovD. A.ЕвстратовД. А.
Russian Federation

1 Leninskie Gory, Moscow 119991, Russia

Россия, 119991 Москва, ул. Ленинские горы, 1

https://orcid.org/0000-0003-4384-6754ZharkovP. A.ЖарковП. А.
Russian Federation

1 Leninskie Gory, Moscow 119991, Russia

Россия, 119991 Москва, ул. Ленинские горы, 1

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава РоссииLomonosov Moscow State UniversityФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова»2607201914224282507201925072019https://oncohematology.abvpress.ru/ongm/article/view/345

Venous thromboembolism is not a rare complication in children with cancer. Despite the advantages of the treatment of venous thromboembolism there is still a probability of venous thromboembolism recurrence. In adult patients with cancer venous thromboembolism recurrence an influence on the lower survival rate. In children with cancer venous thromboembolism recurrence is a rare complication, but it can significantly reduce the quality of life. Risk factors of venous thromboembolism recurrence in children with cancer are not properly investigated.

Венозный тромбоз у детей со злокачественными заболеваниями – нередкое осложнение. Несмотря на успешное лечение, сохраняется вероятность развития рецидива тромбоза глубоких вен. Рецидивы тромбоза глубоких вен у детей со злокачественными заболеваниями являются редким осложнением, значительно снижающим качество жизни, тогда как у взрослых рецидивы тромбоза глубоких вен отрицательно влияют на выживаемость, ограничивая эффективность проводимого лечения. Факторы риска, влияющие на развитие рецидива тромбоза глубоких вен у детей, особенно госпитализированных для лечения злокачественных заболеваний, изучены недостаточно.

venous thromboembolismrecurrent thrombosischildrendeep vein thrombosiscancerleukemiaвенозный тромбозрецидивдетитромбоз глубоких венраклейкозNaess I.A., Christiansen S.C., Romundstad P. et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007;5(4):692–9. DOI: 10.1111/j.1538-7836.2007.02450.x.Raffini L., Huang Y.S., Witmer C., Feudtner C. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics 2009;124(4):1001–8. DOI: 10.1542/peds.2009-0768.Raffini L., Huang Y.S., Witmer C., Feudtner C. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics 2009;124(4):1001–8. DOI: 10.1542/peds.2009-0768.O’Brien S.H., Klima J., Termuhlen A.M., Kelleher K.J. Venous thromboembolism and adolescent and young adult oncology inpatients in US children’s hospitals, 2001 to 2008. J Pediatr 2011;159(1):133–7. DOI: 10.1016/j.jpeds.2011.01.005.O’Brien S.H., Klima J., Termuhlen A.M., Kelleher K.J. Venous thromboembolism and adolescent and young adult oncology inpatients in US children’s hospitals, 2001 to 2008. J Pediatr 2011;159(1):133–7. DOI: 10.1016/j.jpeds.2011.01.005.Prandoni P., Lensing A.W., Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100(10):3484–8. DOI: 10.1182/blood-2002-01-0108.O’Brien S.H., Klima J., Termuhlen A.M., Kelleher K.J. Venous thromboembolism and adolescent and young adult oncology inpatients in US children’s hospitals, 2001 to 2008. J Pediatr 2011;159(1):133–7. DOI: 10.1016/j.jpeds.2011.01.005.Nadir Y., Brenner B. Cancer and thrombosis-new insights. Rambam Maimonides Med J 2018. DOI: 10.5041/RMMJ.10349.Prandoni P., Lensing A.W., Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100(10):3484–8. DOI: 10.1182/blood-2002-01-0108.Ogren M., Bergqvist D., Wahlander K. et al. Trousseau’s syndrome – what is the evidence? A population-based autopsy study. Thromb Haemost 2006;95(3): 541–5. DOI: 10.1160/TH05-10-0694.Prandoni P., Lensing A.W., Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100(10):3484–8. DOI: 10.1182/blood-2002-01-0108.White R.H. The epidemiology of venous thromboembolism. Circulation 2003;107 (23 Suppl 1):14–8. DOI: 10.1161/01.CIR.0000078468.11849.66.Nadir Y., Brenner B. Cancer and thrombosis-new insights. Rambam Maimonides Med J 2018. DOI: 10.5041/RMMJ.10349.Andrew M., David M., Adams M. et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994;83(5):1251–7.Nadir Y., Brenner B. Cancer and thrombosis-new insights. Rambam Maimonides Med J 2018. DOI: 10.5041/RMMJ.10349.van Ommen C.H., Heijboer H., Büller H.R. et al. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr 2001;139(5):676–81. DOI: 10.1067/mpd.2001.118192.Ogren M., Bergqvist D., Wahlander K. et al. Trousseau’s syndrome – what is the evidence? A population-based autopsy study. Thromb Haemost 2006;95(3): 541–5. DOI: 10.1160/TH05-10-0694.Nowak-Gottl U., von Kries R., Gobel U. Neonatal symptomatic thromboembolism in Germany: two year survey. Arch Dis Child Fetal Neonatal Ed 1997;76(3):F163–7.Ogren M., Bergqvist D., Wahlander K. et al. Trousseau’s syndrome – what is the evidence? A population-based autopsy study. Thromb Haemost 2006;95(3): 541–5. DOI: 10.1160/TH05-10-0694.Mitchell L., Andrew M., Hanna K. et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 2003;90(2):235–44. DOI: 10.1160/TH02-11-0283.White R.H. The epidemiology of venous thromboembolism. Circulation 2003;107 (23 Suppl 1):14–8. DOI: 10.1161/01.CIR.0000078468.11849.66.Жарков П.А., Морозова Д.С., Гобадзе Д.А. и др. Тромбозы глубоких вен у детей с заболеваниями крови. Онкогематология 2019;14(1):20–30. DOI: 10.17650/1818-8346-2019-14-1-20-30.White R.H. The epidemiology of venous thromboembolism. Circulation 2003;107 (23 Suppl 1):14–8. DOI: 10.1161/01.CIR.0000078468.11849.66.Athale U.H., Chan A.K.C. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res 2003;111(4–5):199–212. DOI: 10.1016/j.thromres.2003.10.007.Andrew M., David M., Adams M. et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994;83(5):1251–7.Caruso V., Iacoviello L., Di Castelnuovo A. et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006;108(7):2216–22. DOI: 10.1182/blood-2006-04-015511.Andrew M., David M., Adams M. et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994;83(5):1251–7.Athale U., Siciliano S., Thabane L. et al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer 2008;51(6):792–7. DOI: 10.1002/pbc.21734.van Ommen C.H., Heijboer H., Büller H.R. et al. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr 2001;139(5):676–81. DOI: 10.1067/mpd.2001.118192.Grace R.F., Dahlberg S.E., Neuberg D. et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol 2011;152(4):452–9. DOI: 10.1111/j.1365-2141.2010.08524.x.van Ommen C.H., Heijboer H., Büller H.R. et al. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr 2001;139(5):676–81. DOI: 10.1067/mpd.2001.118192.Wermes C., von Depka Prondzinski M., Lichtinghagen R. et al. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr 1999;158(Suppl 3):S143–6.Nowak-Gottl U., von Kries R., Gobel U. Neonatal symptomatic thromboembolism in Germany: two year survey. Arch Dis Child Fetal Neonatal Ed 1997;76(3):F163–7.Athale U.H., Siciliano S.A., Crowther M. et al. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br J Haematol 2005;129(6):803–10. DOI: 10.1111/j.1365-2141.2005.05528.x.Nowak-Gottl U., von Kries R., Gobel U. Neonatal symptomatic thromboembolism in Germany: two year survey. Arch Dis Child Fetal Neonatal Ed 1997;76(3):F163–7.Athale U.H., Nagel K., Khan A.A., Chan A.K.C. Thromboembolism in children with lymphoma. Thromb Res 2008;122(4):459–65. DOI: 10.1016/j.thromres.2007.12.006.Mitchell L., Andrew M., Hanna K. et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 2003;90(2):235–44. DOI: 10.1160/TH02-11-0283.Евстратов Д.А., Жарков П.А., Пшонкин А.В. и др. Венозные тромбозы у детей и подростков с лимфомой Ходжкина. Педиатрия 2018;97(4):30–6.Mitchell L., Andrew M., Hanna K. et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 2003;90(2):235–44. DOI: 10.1160/TH02-11-0283.Tabori U., Beni-Adani L., Dvir R. et al. Risk of venous thromboembolism in pediatric patients with brain tumors. Pediatr Blood Cancer 2004;43(6):633–6. DOI: 10.1002/pbc.20149.Zharkov P.A., Morozova D.S., Gobadze D.A. et al. Deep veins thrombosis in children with blood diseases. Onkogematologiya = Oncohematology 2019;14(1):20–30. (In Russ.). DOI: 10.17650/1818-8346-2019-14-1-20-30.Deitcher S.R., Gajjar A., Kun L., Heideman R.L. Clinically evident venous thromboembolic events in children with brain tumors. J Pediatr 2004;145(6):848–50. DOI: 10.1016/j.jpeds.2004.05.055.Zharkov P.A., Morozova D.S., Gobadze D.A. et al. Deep veins thrombosis in children with blood diseases. Onkogematologiya = Oncohematology 2019;14(1):20–30. (In Russ.). DOI: 10.17650/1818-8346-2019-14-1-20-30.Al-Mateen M., Hood M., Trippel D. et al. Cerebral embolism from atrial myxoma in pediatric patients. Pediatrics 2003;112(2):e162–7.Athale U.H., Chan A.K.C. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res 2003;111(4–5):199–212. DOI: 10.1016/j.thromres.2003.10.007.Paz-Priel I., Long L., Helman L.J. et al. Thromboembolic events in children and young adults with pediatric sarcoma. J Clin Oncol 2007;25(12):1519–24. DOI: 10.1200/JCO.2006.06.9930.Athale U.H., Chan A.K.C. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res 2003;111(4–5):199–212. DOI: 10.1016/j.thromres.2003.10.007.Khorana A.A., Francis C.W., Kuderer N.M. et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thromb Res 2017;151:89–95. DOI: 10.1016/j.thromres.2017.01.009.Caruso V., Iacoviello L., Di Castelnuovo A. et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006;108(7):2216–22. DOI: 10.1182/blood-2006-04-015511.Heit J.A., O’Fallon W.M., Petterson T.M. et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002;162(11):1245–8. DOI: 10.1001/archinte.162.11.1245.Caruso V., Iacoviello L., Di Castelnuovo A. et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006;108(7):2216–22. DOI: 10.1182/blood-2006-04-015511.Hansson P.O., Sorbo J., Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160(6):769–74. DOI: 10.1001/archinte.160.6.769.Athale U., Siciliano S., Thabane L. et al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer 2008;51(6):792–7. DOI: 10.1002/pbc.21734.Khorana A.A. Venous thromboembolism and prognosis in cancer. Thromb Res 2010;125(6):490–3. DOI: 10.1016/j.thromres.2009.12.023.Athale U., Siciliano S., Thabane L. et al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer 2008;51(6):792–7. DOI: 10.1002/pbc.21734.Douketis J.D., Foster G.A., Crowther M.A. et al. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 2000;160(22):3431–6. DOI: 10.1001/archinte.160.22.3431.Grace R.F., Dahlberg S.E., Neuberg D. et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol 2011;152(4):452–9. DOI: 10.1111/j.1365-2141.2010.08524.x.Nowak-Gottl U., Junker R., Kreuz W. et al. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001;97(4):858–62.Grace R.F., Dahlberg S.E., Neuberg D. et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol 2011;152(4):452–9. DOI: 10.1111/j.1365-2141.2010.08524.x.López-Núñez J.J., Trujillo-Santos J., Monreal M. Management of venous thromboembolism in patients with cancer. J Thromb Haemost 2018;16(12):2391–6. DOI: 10.1111/jth.14305.Wermes C., von Depka Prondzinski M., Lichtinghagen R. et al. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr 1999;158(Suppl 3):S143–6.Prandoni P., Noventa F., Ghirarduzzi A. et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007;92(2):199–205. DOI: 10.3324/haematol.10516.Wermes C., von Depka Prondzinski M., Lichtinghagen R. et al. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr 1999;158(Suppl 3):S143–6.Kulkarni K., Forbrigger Z., Moorehead P.C. et al. Correction to: the association of venous thromboembolism with survival in pediatric cancer patients: a populationbased cohort study. Ann Hematol 2018;97(9):1743. DOI: 10.1007/s00277-018-3394-6.Athale U.H., Siciliano S.A., Crowther M. et al. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br J Haematol 2005;129(6):803–10. DOI: 10.1111/j.1365-2141.2005.05528.x.Monagle P., Adams M., Mahoney M. et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res 2000;47(6):763–6.Athale U.H., Siciliano S.A., Crowther M. et al. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br J Haematol 2005;129(6):803–10. DOI: 10.1111/j.1365-2141.2005.05528.x.Guy Y., Albisetti M., Bonduel M. et al. Impact of inherited thrombophilia on venous thromboembolism in children. Circulation 2008;118(13):1373–82. DOI: 10.1161/CIRCULATIONAHA.108.789008.Athale U.H., Nagel K., Khan A.A., Chan A.K.C. Thromboembolism in children with lymphoma. Thromb Res 2008;122(4):459–65. DOI: 10.1016/j.thromres.2007.12.006.Ho W.K., Hankey G.J., Quinlan D.J., Eikelboom J.W. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006;166(7):729–76. DOI: 10.1001/archinte.166.7.729.Athale U.H., Nagel K., Khan A.A., Chan A.K.C. Thromboembolism in children with lymphoma. Thromb Res 2008;122(4):459–65. DOI: 10.1016/j.thromres.2007.12.006.Rank C.U., Toft N., Tuckuviene R. et al. Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. Blood 2018;131(22):2475–84. DOI: 10.1182/blood-2018-01-827949.Evstratov D.A., Zharkov P.A., Pshonkin A.V. et al. Venous thrombosis in children and adolescents with Hodgkin's lymphoma. Pediatriya = Pediatrics 2018;97(4):30–6. (In Russ.).Klaassen I.L.M., van Els A.L., van de Wetering M.D., van Ommen C.H. Increasing incidence and recurrence rate of venous thromboembolism in paediatric oncology patients in one single centre over 25 years. Thromb Haemost 2017;117(11):2156–62. DOI: 10.1160/TH17-02-0109.Evstratov D.A., Zharkov P.A., Pshonkin A.V. et al. Venous thrombosis in children and adolescents with Hodgkin's lymphoma. Pediatriya = Pediatrics 2018;97(4):30–6. (In Russ.).Carrier M., Khorana A.A., Zwicker J.I. et al. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. J Thromb Haemost 2013;11(9):1760–5. DOI: 10.1111/jth.12338.Tabori U., Beni-Adani L., Dvir R. et al. Risk of venous thromboembolism in pediatric patients with brain tumors. Pediatr Blood Cancer 2004;43(6):633–6. DOI: 10.1002/pbc.20149.Tullius B.P., Athale U., van Ommen C.H., et al. The identification of at-risk patients and prevention of venous thromboembolism in pediatric cancer: guidance from the SSC of the ISTH. J Thromb Haemost 2018;16(1):175–80. DOI: 10.1111/jth.13895.Tabori U., Beni-Adani L., Dvir R. et al. Risk of venous thromboembolism in pediatric patients with brain tumors. Pediatr Blood Cancer 2004;43(6):633–6. DOI: 10.1002/pbc.20149.Deitcher S.R., Gajjar A., Kun L., Heideman R.L. Clinically evident venous thromboembolic events in children with brain tumors. J Pediatr 2004;145(6):848–50. DOI: 10.1016/j.jpeds.2004.05.055.Deitcher S.R., Gajjar A., Kun L., Heideman R.L. Clinically evident venous thromboembolic events in children with brain tumors. J Pediatr 2004;145(6):848–50. DOI: 10.1016/j.jpeds.2004.05.055.Al-Mateen M., Hood M., Trippel D. et al. Cerebral embolism from atrial myxoma in pediatric patients. Pediatrics 2003;112(2):e162–7.Al-Mateen M., Hood M., Trippel D. et al. Cerebral embolism from atrial myxoma in pediatric patients. Pediatrics 2003;112(2):e162–7.Paz-Priel I., Long L., Helman L.J. et al. Thromboembolic events in children and young adults with pediatric sarcoma. J Clin Oncol 2007;25(12):1519–24. DOI: 10.1200/JCO.2006.06.9930.Paz-Priel I., Long L., Helman L.J. et al. Thromboembolic events in children and young adults with pediatric sarcoma. J Clin Oncol 2007;25(12):1519–24. DOI: 10.1200/JCO.2006.06.9930.Khorana A.A., Francis C.W., Kuderer N.M. et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thromb Res 2017;151:89–95. DOI: 10.1016/j.thromres.2017.01.009.Khorana A.A., Francis C.W., Kuderer N.M. et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thromb Res 2017;151:89–95. DOI: 10.1016/j.thromres.2017.01.009.Heit J.A., O’Fallon W.M., Petterson T.M. et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002;162(11):1245–8. DOI: 10.1001/archinte.162.11.1245.Heit J.A., O’Fallon W.M., Petterson T.M. et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002;162(11):1245–8. DOI: 10.1001/archinte.162.11.1245.Hansson P.O., Sorbo J., Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160(6):769–74. DOI: 10.1001/archinte.160.6.769.Hansson P.O., Sorbo J., Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160(6):769–74. DOI: 10.1001/archinte.160.6.769.Khorana A.A. Venous thromboembolism and prognosis in cancer. Thromb Res 2010;125(6):490–3. DOI: 10.1016/j.thromres.2009.12.023.Khorana A.A. Venous thromboembolism and prognosis in cancer. Thromb Res 2010;125(6):490–3. DOI: 10.1016/j.thromres.2009.12.023.Douketis J.D., Foster G.A., Crowther M.A. et al. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 2000;160(22):3431–6. DOI: 10.1001/archinte.160.22.3431.Douketis J.D., Foster G.A., Crowther M.A. et al. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 2000;160(22):3431–6. DOI: 10.1001/archinte.160.22.3431.Nowak-Gottl U., Junker R., Kreuz W. et al. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001;97(4):858–62.Nowak-Gottl U., Junker R., Kreuz W. et al. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001;97(4):858–62.López-Núñez J.J., Trujillo-Santos J., Monreal M. Management of venous thromboembolism in patients with cancer. J Thromb Haemost 2018;16(12):2391–6. DOI: 10.1111/jth.14305.López-Núñez J.J., Trujillo-Santos J., Monreal M. Management of venous thromboembolism in patients with cancer. J Thromb Haemost 2018;16(12):2391–6. DOI: 10.1111/jth.14305.Prandoni P., Noventa F., Ghirarduzzi A. et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007;92(2):199–205. DOI: 10.3324/haematol.10516.Prandoni P., Noventa F., Ghirarduzzi A. et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007;92(2):199–205. DOI: 10.3324/haematol.10516.Kulkarni K., Forbrigger Z., Moorehead P.C. et al. Correction to: the association of venous thromboembolism with survival in pediatric cancer patients: a populationbased cohort study. Ann Hematol 2018;97(9):1743. DOI: 10.1007/s00277-018-3394-6.Kulkarni K., Forbrigger Z., Moorehead P.C. et al. Correction to: the association of venous thromboembolism with survival in pediatric cancer patients: a populationbased cohort study. Ann Hematol 2018;97(9):1743. DOI: 10.1007/s00277-018-3394-6.Monagle P., Adams M., Mahoney M. et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res 2000;47(6):763–6.Monagle P., Adams M., Mahoney M. et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res 2000;47(6):763–6.Guy Y., Albisetti M., Bonduel M. et al. Impact of inherited thrombophilia on venous thromboembolism in children. Circulation 2008;118(13):1373–82. DOI: 10.1161/CIRCULATIONAHA.108.789008.Guy Y., Albisetti M., Bonduel M. et al. Impact of inherited thrombophilia on venous thromboembolism in children. Circulation 2008;118(13):1373–82. DOI: 10.1161/CIRCULATIONAHA.108.789008.Ho W.K., Hankey G.J., Quinlan D.J., Eikelboom J.W. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006;166(7):729–76. DOI: 10.1001/archinte.166.7.729.Ho W.K., Hankey G.J., Quinlan D.J., Eikelboom J.W. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006;166(7):729–76. DOI: 10.1001/archinte.166.7.729.Rank C.U., Toft N., Tuckuviene R. et al. Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. Blood 2018;131(22):2475–84. DOI: 10.1182/blood-2018-01-827949.Rank C.U., Toft N., Tuckuviene R. et al. Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. Blood 2018;131(22):2475–84. DOI: 10.1182/blood-2018-01-827949.Klaassen I.L.M., van Els A.L., van de Wetering M.D., van Ommen C.H. Increasing incidence and recurrence rate of venous thromboembolism in paediatric oncology patients in one single centre over 25 years. Thromb Haemost 2017;117(11):2156–62. DOI: 10.1160/TH17-02-0109.Klaassen I.L.M., van Els A.L., van de Wetering M.D., van Ommen C.H. Increasing incidence and recurrence rate of venous thromboembolism in paediatric oncology patients in one single centre over 25 years. Thromb Haemost 2017;117(11):2156–62. DOI: 10.1160/TH17-02-0109.Carrier M., Khorana A.A., Zwicker J.I. et al. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. J Thromb Haemost 2013;11(9):1760–5. DOI: 10.1111/jth.12338.Carrier M., Khorana A.A., Zwicker J.I. et al. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. J Thromb Haemost 2013;11(9):1760–5. DOI: 10.1111/jth.12338.Tullius B.P., Athale U., van Ommen C.H., et al. The identification of at-risk patients and prevention of venous thromboembolism in pediatric cancer: guidance from the SSC of the ISTH. J Thromb Haemost 2018;16(1):175–80. DOI: 10.1111/jth.13895.Tullius B.P., Athale U., van Ommen C.H., et al. The identification of at-risk patients and prevention of venous thromboembolism in pediatric cancer: guidance from the SSC of the ISTH. J Thromb Haemost 2018;16(1):175–80. DOI: 10.1111/jth.13895.